Direct Answer
Research reagent companies make the antibodies, enzymes, cell culture media and chemicals that labs use in experiments and drug development. Revenue is recurring consumables bought repeatedly by academic, biotech and pharma customers.
Industry Overview
Research Reagents sits within the health care sector. The first numbers to compare across companies here are organic growth, gross margin and consumables share of revenue. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Organic growth: Sales growth excluding acquisitions and currency effects. Because lab customers reorder, it follows research funding and lab activity, and can drop when distributors reduce stock.
- Gross margin: Share of sales left after the cost of making and packaging reagents. Specialty products with unique quality earn higher margins, while commodity chemicals compete on price.
- Consumables share of revenue: Portion of sales that are used up and reordered. A high share creates repeat revenue tied to lab activity rather than to one-off equipment purchases.
- Customer mix of academia and industry: Split of sales between universities and drug or biotech companies. Academic buyers follow grant budgets, while industry buyers follow development pipelines, so the mix shapes cyclicality.
- Catalog size and new products: Number of products offered and recent additions. A broad catalog makes a supplier convenient for labs, and new products help defend share against alternatives.
Primary Macro Drivers
- Research funding and biotech spending: Labs reorder antibodies, media and enzymes as experiments run, so research and biotech spending moves organic growth directly.
- Drug development pipelines: More drug programs in development mean more experiments and process work, which supports consumables demand from industry customers.
- Academic grant budgets: Universities and institutes buy through grants, so changes in grant budgets move sales to academic customers.
- Distribution channel inventory: Distributors hold stock between makers and labs, so when they build or run down inventory, makers' sales shift apart from lab use.
Major Risks
- Funding cyclicality: Grant and venture funding go through cycles, and when they tighten customers cut purchases; watch the mix of academic and industry customers and organic growth.
- Distributor destocking: When distributors reduce stock, shipments fall below actual lab use for a period; watch distributor inventory commentary and sales trends.
- Competition and price pressure: Many suppliers sell similar items, so price competition can narrow gross margin; watch gross margin and new products added.
- Quality and lot variability: Batch differences can invalidate experiments and lead customers to switch; watch complaint and quality disclosures and repeat purchases.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Mixed |
| Capital Intensity | Medium |
| Regulatory Intensity | Low |
| Industry Maturity | Mature |
| Geographic Importance | Global |
Companies Associated with Research Reagents
The SEC's Standard Industrial Classification has no code that describes research reagents as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.
| Company | SEC classification | Revenue | Growth | Net margin | Year |
|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. | Measuring & Controlling Devices, Nec | $44.6 billion | 3.9% | 15.1% | FY 2025 |
| Avantor, Inc. | Laboratory Analytical Instruments | $6.6 billion | -3.4% | -8.1% | FY 2025 |
| Bio-Techne Corp | Biological Products, (No Diagnostic Substances) | $1.2 billion | 5.2% | 6.0% | FY 2025 |
Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.
Where to Go Next
The Research Reagents guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Respiratory Devices
- Research & Manufacturing Services
- Retail Pharmacies
- Remote Patient Monitoring
- Revenue Cycle Management
- Regenerative Medicine
- RNA Therapeutics
- Rare Disease Pharmaceuticals
Put it to work
Frequently Asked Questions
What are the main KPIs for the Research Reagents industry?
Key performance indicators for the Research Reagents industry include: Organic growth, Gross margin, Consumables share of revenue, Customer mix of academia and industry, Catalog size and new products. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Research Reagents industry?
The Research Reagents industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.
What are the biggest risks in the Research Reagents industry?
The primary risks for Research Reagents companies include: Funding cyclicality, Distributor destocking, Competition and price pressure, Quality and lot variability. Investors should assess each company's exposure to these factors and its track record of navigating them.